Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 5/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50338 | 1.00 | BCAT2 (0.68) | BCAT2NPC1RAB9ASMN1; SMN2MTNR1A | |
| SCHEMBL885090 | 1.00 | BCAT2 (0.68) | BCAT2NPC1RAB9ASMN1; SMN2MTNR1A | |
| Acetic Acid SCHEMBL8330086 | 0.98 | BCAT2 (0.66) | BCAT2NPC1RAB9ASMN1; SMN2MTNR1A | |
| SCHEMBL2091812 | 0.84 | MTNR1A (0.67) | BCAT2NPC1RAB9AMTNR1AMTNR1B | |
| SCHEMBL1520684 | 0.84 | BCAT2 (0.72) | BCAT2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL26906281 | 0.84 | BCAT2 (0.72) | BCAT2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL17469083 | 0.83 | NPC1 (0.64) | BCAT2NPC1RAB9ASMN1; SMN2MTNR1A | |
| SCHEMBL11436581 | 0.82 | MTNR1A (0.62) | BCAT2NPC1RAB9ASMN1; SMN2MTNR1A | |
| Acetic Acid SCHEMBL8948216 | 0.82 | KDM4E (0.80) | BCAT2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL8047567 | 0.81 | SMN1; SMN2 (0.64) | BCAT2NPC1RAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148537-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2012-04-03 | — | — | US | claimed |
| EP-2125736-B1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA AS (DK) | 2011-03-30 | — | — | EP | claimed |
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA (DK) | 2010-02-11 | — | — | US | claimed |
| CN-101611005-A | Be used as the acetophenones of the replacement of PDE4 inhibitor | LEO PHARMA AS (DK) | 2009-12-23 | — | — | CN | claimed |
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | claimed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | claimed |
| JP-6100514-A | — | — | None | — | — | JP | disclosed |
| JP-6092920-A | — | — | None | — | — | JP | disclosed |
| CN-101611005-B | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA AS | 2013-11-06 | — | — | CN | disclosed |
| US-8497380-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2013-07-30 | — | — | US | disclosed |
| US-20130012716-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | FELDING JAKOB (DK) | 2013-01-10 | — | — | US | disclosed |
| US-8324394-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2012-12-04 | — | — | US | disclosed |
| US-20120220567-A1 | BENZO-FUSED OXAZEPINE COMPOUNDS AS STEAROYL-COENZYME A DELTA-9 DESATURASE INHIBITORS | SCHERING CORPORATION | 2012-08-30 | — | — | US | disclosed |
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | disclosed |
| WO-1998027051-A9 | CATALYTIC ASYMMETRIC AMIDOHYDROXYLATION OF OLEFINS WITH N-HALO CARBOXAMIDES | — | 1998-11-12 | — | — | WO | disclosed |
| WO-1998027051-A2 | CATALYTIC ASYMMETRIC AMIDOHYDROXYLATION OF OLEFINS WITH N-HALO CARBOXAMIDES | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-06-25 | — | — | WO | disclosed |
| JP-H06100514-A | OPTICALLY ACTIVE @(3754/24)S)-AND (R)-2-ACYLAMINO-1-ARYLETHANOL DERIVATIVE AND THEIR PRODUCTION | KAWAKEN FINE CHEM CO LTD | 1994-04-12 | — | — | JP | disclosed |
| JP-H0692920-A | OPTICALLY ACTIVE @(3754/24)R)-2-ACYLAMINO-1-ARYLETHANOL DERIVATIVE AND ITS PRODUCTION | KAWAKEN FINE CHEM CO LTD | 1994-04-05 | — | — | JP | disclosed |
| JP-H00692920-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220567-A1 | BENZO-FUSED OXAZEPINE COMPOUNDS AS STEAROYL-COENZYME A DELTA-9 DESATURASE INHIBITORS | SCD, SCD5, CPT1A | BCAT2 689/4885NPC1 582/4885RAB9A 2573/4885 |
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE3B | BCAT2 3563/4885NPC1 2847/4885RAB9A 4359/4885 |
| US-20130012716-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | PDE4A, PDE3B, PDE5A | BCAT2 3830/4885NPC1 2749/4885RAB9A 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.